兴齐眼药：公司另外两种浓度的硫酸阿托品滴眼液（0.02%和0.04%）已取得Ⅲ期临床试验总结报告

Core Viewpoint - The company emphasizes its competitive advantage with the only approved eye medication for delaying myopia progression in children, while maintaining stable pricing despite market competition and potential new entrants [1] Group 1 - The company has the first and only officially approved eye medication in China for delaying myopia progression in children, known as Xingqi® Meiyoupin® [1] - Two additional concentrations of atropine eye drops (0.02% and 0.04%) have completed phase III clinical trial summary reports, which will enhance the company's myopia prevention product matrix upon their market launch [1] - Currently, the approved product is not included in centralized procurement, allowing the company to maintain stable pricing in the competitive market [1]